3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
cyclopia sequence
6
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Breast Neoplasms
6
Lung Neoplasms
4
Dyspnea
4
Recurrence
3
Primary Myelofibrosis
3
Oropharyngeal Neoplasms
3
Multiple Myeloma
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Polycythemia Vera
2
Pain
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thrombocythemia, Essential
1
Splenomegaly
1
Speech
1
Sezary Syndrome
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plexosarcoma
1
Pathologic Complete Response
1
Interventions
Paclitaxel
56
Carboplatin
56
Bevacizumab
43
Gemcitabine
20
Taxes
19
pembrolizumab
15
Immunoglobulin G
13
Disulfides
13
Topotecan
12
olaparib
11
Cisplatin
11
niraparib
9
Cyclophosphamide
9
liposomal doxorubicin
8
Specimen Handling
7
Docetaxel
6
Biopsy
6
mirvetuximab soravtansine
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Letrozole
5
Hyperthermic Intraperitoneal Chemotherapy
5
Drug Therapy
5
Cytoreduction Surgical Procedures
5
Albumin-Bound Paclitaxel
5
rucaparib
4
pazopanib
4
oregovomab
4
Surgical Procedures, Operative
4
Neoadjuvant Therapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Fallopian Tube Neoplasms
×
Surveys and Questionnaires
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled